25 XP   0   0   10

Deciphera Pharmaceuticals LLC
Buy, Hold or Sell?

Let's analyse Deciphera together

PenkeI guess you are interested in Deciphera Pharmaceuticals LLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Deciphera Pharmaceuticals LLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Deciphera Pharmaceuticals LLC

I send you an email if I find something interesting about Deciphera Pharmaceuticals LLC.

Quick analysis of Deciphera (30 sec.)










What can you expect buying and holding a share of Deciphera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.05
Expected worth in 1 year
$3.87
How sure are you?
29.0%

+ What do you gain per year?

Total Gains per Share
$-0.18
Return On Investment
-1.2%

For what price can you sell your share?

Current Price per Share
$14.67
Expected price per share
$13.17 - $15.81
How sure are you?
50%

1. Valuation of Deciphera (5 min.)




Live pricePrice per Share (EOD)

$14.67

Intrinsic Value Per Share

$-3.75 - $-3.54

Total Value Per Share

$0.30 - $0.51

2. Growth of Deciphera (5 min.)




Is Deciphera growing?

Current yearPrevious yearGrowGrow %
How rich?$350.9m$348m$46.2m11.7%

How much money is Deciphera making?

Current yearPrevious yearGrowGrow %
Making money-$48.7m-$43.2m-$5.4m-11.2%
Net Profit Margin-121.8%-130.4%--

How much money comes from the company's main activities?

3. Financial Health of Deciphera (5 min.)




What can you expect buying and holding a share of Deciphera? (5 min.)

Welcome investor! Deciphera's management wants to use your money to grow the business. In return you get a share of Deciphera.

What can you expect buying and holding a share of Deciphera?

First you should know what it really means to hold a share of Deciphera. And how you can make/lose money.

Speculation

The Price per Share of Deciphera is $14.67. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Deciphera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Deciphera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.05. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Deciphera.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.54-3.7%-0.57-3.9%-0.55-3.8%-0.69-4.7%-0.53-3.6%
Usd Book Value Change Per Share-0.40-2.7%-0.05-0.3%0.110.8%0.030.2%0.130.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.40-2.7%-0.05-0.3%0.110.8%0.030.2%0.130.9%
Usd Price Per Share16.13-14.60-14.33-29.60-24.29-
Price to Earnings Ratio-7.41--6.38--6.51--10.68--11.24-
Price-to-Total Gains Ratio-40.17--23.06--25.94--47.47--46.79-
Price to Book Ratio3.99-3.18-3.31-5.39-4.65-
Price-to-Total Gains Ratio-40.17--23.06--25.94--47.47--46.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.67
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.050.03
Usd Total Gains Per Share-0.050.03
Gains per Quarter (68 shares)-3.081.98
Gains per Year (68 shares)-12.347.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-12-2208-2
20-25-340166
30-37-4602414
40-49-5803222
50-62-7004030
60-74-8204838
70-86-9405546
80-99-10606354
90-111-11807162
100-123-13007970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.030.00.03.2%1.030.00.03.2%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.021.01.029.0%9.021.01.029.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.031.00.0%0.00.031.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.021.01.029.0%9.021.01.029.0%

Fundamentals of Deciphera

About Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 05:52:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Deciphera Pharmaceuticals LLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Deciphera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -97.7% means that $-0.98 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is -97.7%. The company is making a huge loss. -2
  • The TTM is -121.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-97.7%TTM-121.8%+24.1%
TTM-121.8%YOY-130.4%+8.6%
TTM-121.8%5Y-6,073.0%+5,951.2%
5Y-6,073.0%10Y-3,918.1%-2,154.9%
1.1.2. Return on Assets

Shows how efficient Deciphera is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • -10.0% Return on Assets means that Deciphera generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is -10.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.0%TTM-9.6%-0.3%
TTM-9.6%YOY-9.6%+0.0%
TTM-9.6%5Y-11.1%+1.5%
5Y-11.1%10Y-13.5%+2.4%
1.1.3. Return on Equity

Shows how efficient Deciphera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • -13.4% Return on Equity means Deciphera generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.4%TTM-12.4%-1.0%
TTM-12.4%YOY-12.8%+0.4%
TTM-12.4%5Y-13.7%+1.3%
5Y-13.7%10Y-14.6%+0.9%

1.2. Operating Efficiency of Deciphera Pharmaceuticals LLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Deciphera is operating .

  • Measures how much profit Deciphera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -106.1% means the company generated $-1.06  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is -106.1%. The company is operating very inefficient. -2
  • The TTM is -132.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-106.1%TTM-132.5%+26.4%
TTM-132.5%YOY-138.5%+6.0%
TTM-132.5%5Y-6,076.9%+5,944.4%
5Y-6,076.9%10Y-3,920.6%-2,156.3%
1.2.2. Operating Ratio

Measures how efficient Deciphera is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.06 means that the operating costs are $2.06 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is 2.061. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.318. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.061TTM2.318-0.257
TTM2.318YOY2.374-0.057
TTM2.3185Y63.610-61.293
5Y63.61010Y41.039+22.571

1.3. Liquidity of Deciphera Pharmaceuticals LLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Deciphera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.80 means the company has $3.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is 3.801. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.742. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.801TTM4.742-0.942
TTM4.742YOY4.957-0.215
TTM4.7425Y7.504-2.762
5Y7.50410Y8.971-1.467
1.3.2. Quick Ratio

Measures if Deciphera is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 5.59 means the company can pay off $5.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is 5.593. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.956. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.593TTM6.956-1.363
TTM6.956YOY7.538-0.582
TTM6.9565Y12.161-5.205
5Y12.16110Y11.296+0.865

1.4. Solvency of Deciphera Pharmaceuticals LLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Deciphera assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Deciphera to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.26 means that Deciphera assets are financed with 25.9% credit (debt) and the remaining percentage (100% - 25.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is 0.259. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.224. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.259TTM0.224+0.035
TTM0.224YOY0.240-0.015
TTM0.2245Y0.180+0.044
5Y0.18010Y0.353-0.173
1.4.2. Debt to Equity Ratio

Measures if Deciphera is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 35.0% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Deciphera Pharmaceuticals LLC:

  • The MRQ is 0.350. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.290. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.350TTM0.290+0.059
TTM0.290YOY0.318-0.028
TTM0.2905Y0.227+0.063
5Y0.22710Y0.182+0.046

2. Market Valuation of Deciphera Pharmaceuticals LLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Deciphera generates.

  • Above 15 is considered overpriced but always compare Deciphera to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -7.41 means the investor is paying $-7.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Deciphera Pharmaceuticals LLC:

  • The EOD is -6.738. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.409. Based on the earnings, the company is expensive. -2
  • The TTM is -6.378. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.738MRQ-7.409+0.671
MRQ-7.409TTM-6.378-1.031
TTM-6.378YOY-6.513+0.135
TTM-6.3785Y-10.685+4.307
5Y-10.68510Y-11.239+0.554
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Deciphera Pharmaceuticals LLC:

  • The EOD is -11.013. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.110. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.836. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.013MRQ-12.110+1.096
MRQ-12.110TTM-8.836-3.274
TTM-8.836YOY-9.063+0.227
TTM-8.8365Y-13.035+4.199
5Y-13.03510Y-14.571+1.536
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Deciphera is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Deciphera Pharmaceuticals LLC:

  • The EOD is 3.625. Based on the equity, the company is fair priced.
  • The MRQ is 3.985. Based on the equity, the company is fair priced.
  • The TTM is 3.177. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.625MRQ3.985-0.361
MRQ3.985TTM3.177+0.809
TTM3.177YOY3.314-0.137
TTM3.1775Y5.391-2.214
5Y5.39110Y4.653+0.737
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Deciphera Pharmaceuticals LLC.

3.1. Institutions holding Deciphera Pharmaceuticals LLC

Institutions are holding 73.379% of the shares of Deciphera Pharmaceuticals LLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Deerfield Management Co8.53661.933168976061905802.8415
2023-12-31BlackRock Inc7.39640.002559762665272609.6763
2023-12-31Armistice Capital, LLC6.43561.145520000058800012.7493
2023-12-31Goldman Sachs Group Inc5.71160.006746149502598443128.8586
2023-09-30Redmile Group, LLC5.53882.70854475384-403182-8.2644
2023-12-31Vanguard Group Inc5.44760.00164401636332030.7601
2023-09-30BRAIDWELL LP4.1291.34113336221-310198-8.5069
2023-12-31State Street Corporation3.05790.001924708131596956.9099
2023-12-31Morgan Stanley - Brokerage Accounts2.86690.0033231643372344845.4146
2023-12-31Polar Capital Holdings PLC2.28960.182818500001000005.7143
2023-12-31Dimensional Fund Advisors, Inc.1.93270.00741561654924106.2896
2023-12-31Nuveen Asset Management, LLC1.74850.00731412799981947.4695
2023-12-31Geode Capital Management, LLC1.51150.00211221308847017.4521
2023-12-31Jefferies Financial Group Inc1.13550.096591751517877224.1995
2023-12-31Assenagon Asset Management SA1.00240.034780992300
2023-09-30Jacobs Levy Equity Management, Inc.0.87510.0533707103-148172-17.3245
2023-12-31Emerald Advisers, LLC0.83080.46346712556712550
2023-12-31Millennium Management LLC0.80720.004665225429806484.1537
2023-09-30Point72 Asset Management, L.P.0.74020.0222598078-20868-3.3715
2023-12-31New Leaf Venture Partners, L.L.C.0.71417.4963576975-632596-52.2992
Total 62.70815.514350668173+4829009+9.5%

3.2. Funds holding Deciphera Pharmaceuticals LLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Polar Capital Biotech S Inc2.28961.7558185000000
2024-03-28SPDR® S&P Biotech ETF2.25020.37881818202229201.2767
2024-02-29Vanguard Total Stock Mkt Idx Inv2.17920.0019176079800
2024-03-28iShares Russell 2000 ETF1.61480.031313047376300.0483
2023-12-31UBS: US Equity Small Cap Growth1.19920.641796892400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.07240.0142866462-933-0.1076
2023-12-31Vanguard Strategic Equity Inv0.92550.154974781600
2024-01-31CREF Stock R10.8530.008468923800
2024-01-31Fidelity Small Cap Index0.67010.031354147985081.5963
2024-02-29Emerald Growth A0.53730.737743414300
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.50590.195440873000
2023-11-30MEDICAL BioHealth EUR Acc0.4840.760639109910000034.3526
2024-03-28iShares Biotechnology ETF0.45520.075836778100
2023-12-31Vanguard Explorer Inv0.45370.027736657700
2024-02-29Fidelity Extended Market Index0.42580.015344080263238.284
2024-02-29DFA US Micro Cap I0.42260.079534148100
2024-03-28iShares Russell 2000 Value ETF0.40620.0412328237-208-0.0633
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.4030.01332560241001.2753
2024-02-29BlackRock Advantage Small Cap Core Instl0.38490.1479310984-18867-5.7199
2024-02-29Principal SmallCap Growth I Instl0.35690.19162883972910.101
Total 17.88955.303714454767+142764+1.0%

3.3. Insider Transactions

Insiders are holding 30.491% of the shares of Deciphera Pharmaceuticals LLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-16Jama PitmanSELL162414.47
2024-01-16Matthew L ShermanSELL243514.47
2023-10-30Jama PitmanSELL140712.02
2023-10-30Matthew L ShermanSELL236012.02
2023-10-30Steven L HoerterSELL2157312.02
2023-10-30Thomas Patrick KellySELL231612.02
2023-10-02Matthew L ShermanSELL294212.68
2023-06-16Jama PitmanSELL123814.4
2023-06-16Matthew L ShermanSELL165514.4
2023-06-08Franklin Stuart FriedmanBUY1000013.88
2023-05-10Dennis Leo WalshBUY1100013.86

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Deciphera Pharmaceuticals LLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.402-0.045-89%0.114-451%0.029-1479%0.131-408%
Book Value Per Share--4.0474.644-13%4.307-6%5.289-23%3.867+5%
Current Ratio--3.8014.742-20%4.957-23%7.504-49%8.971-58%
Debt To Asset Ratio--0.2590.224+15%0.240+8%0.180+44%0.353-27%
Debt To Equity Ratio--0.3500.290+20%0.318+10%0.227+54%0.182+92%
Dividend Per Share----0%-0%-0%-0%
Eps---0.544-0.573+5%-0.554+2%-0.695+28%-0.529-3%
Free Cash Flow Per Share---0.333-0.435+31%-0.476+43%-0.582+75%-0.436+31%
Free Cash Flow To Equity Per Share---0.3230.022-1543%0.034-1048%0.031-1137%0.141-328%
Gross Profit Margin--1.0001.0000%1.0000%1.015-2%1.010-1%
Intrinsic Value_10Y_max---3.538--------
Intrinsic Value_10Y_min---3.751--------
Intrinsic Value_1Y_max---1.965--------
Intrinsic Value_1Y_min---1.931--------
Intrinsic Value_3Y_max---4.676--------
Intrinsic Value_3Y_min---4.489--------
Intrinsic Value_5Y_max---5.907--------
Intrinsic Value_5Y_min---5.589--------
Market Cap1185337408.320-18%1398503663.2501241043776.233+13%1157663375.440+21%2404399717.055-42%1970239283.034-29%
Net Profit Margin---0.977-1.218+25%-1.304+33%-60.730+6115%-39.181+3910%
Operating Margin---1.061-1.325+25%-1.385+31%-60.769+5628%-39.206+3595%
Operating Ratio--2.0612.318-11%2.374-13%63.610-97%41.039-95%
Pb Ratio3.625-10%3.9853.177+25%3.314+20%5.391-26%4.653-14%
Pe Ratio-6.738+9%-7.409-6.378-14%-6.513-12%-10.685+44%-11.239+52%
Price Per Share14.670-10%16.13014.595+11%14.328+13%29.605-46%24.285-34%
Price To Free Cash Flow Ratio-11.013+9%-12.110-8.836-27%-9.063-25%-13.035+8%-14.571+20%
Price To Total Gains Ratio-36.531+9%-40.166-23.057-43%-25.940-35%-47.475+18%-46.786+16%
Quick Ratio--5.5936.956-20%7.538-26%12.161-54%11.296-50%
Return On Assets---0.100-0.096-3%-0.096-3%-0.111+11%-0.135+35%
Return On Equity---0.134-0.124-8%-0.128-5%-0.137+2%-0.146+9%
Total Gains Per Share---0.402-0.045-89%0.114-451%0.029-1479%0.131-408%
Usd Book Value--350916000.000394275000.000-11%348010750.000+1%431179450.000-19%314900580.645+11%
Usd Book Value Change Per Share---0.402-0.045-89%0.114-451%0.029-1479%0.131-408%
Usd Book Value Per Share--4.0474.644-13%4.307-6%5.289-23%3.867+5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.544-0.573+5%-0.554+2%-0.695+28%-0.529-3%
Usd Free Cash Flow---28872000.000-36868750.000+28%-38497500.000+33%-47374450.000+64%-35466483.871+23%
Usd Free Cash Flow Per Share---0.333-0.435+31%-0.476+43%-0.582+75%-0.436+31%
Usd Free Cash Flow To Equity Per Share---0.3230.022-1543%0.034-1048%0.031-1137%0.141-328%
Usd Market Cap1185337408.320-18%1398503663.2501241043776.233+13%1157663375.440+21%2404399717.055-42%1970239283.034-29%
Usd Price Per Share14.670-10%16.13014.595+11%14.328+13%29.605-46%24.285-34%
Usd Profit---47190000.000-48735500.000+3%-43254500.000-8%-56333450.000+19%-42299322.581-10%
Usd Revenue--48294000.00040839000.000+18%33509000.000+44%23031350.000+110%14858935.484+225%
Usd Total Gains Per Share---0.402-0.045-89%0.114-451%0.029-1479%0.131-408%
 EOD+3 -5MRQTTM+15 -18YOY+15 -185Y+15 -1910Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Deciphera Pharmaceuticals LLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.738
Price to Book Ratio (EOD)Between0-13.625
Net Profit Margin (MRQ)Greater than0-0.977
Operating Margin (MRQ)Greater than0-1.061
Quick Ratio (MRQ)Greater than15.593
Current Ratio (MRQ)Greater than13.801
Debt to Asset Ratio (MRQ)Less than10.259
Debt to Equity Ratio (MRQ)Less than10.350
Return on Equity (MRQ)Greater than0.15-0.134
Return on Assets (MRQ)Greater than0.05-0.100
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Deciphera Pharmaceuticals LLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.628
Ma 20Greater thanMa 5015.159
Ma 50Greater thanMa 10015.648
Ma 100Greater thanMa 20015.202
OpenGreater thanClose14.170
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -983802-181-786-96771-8961,473577



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets473,566
Total Liabilities122,650
Total Stockholder Equity350,916
 As reported
Total Liabilities 122,650
Total Stockholder Equity+ 350,916
Total Assets = 473,566

Assets

Total Assets473,566
Total Current Assets381,096
Long-term Assets92,470
Total Current Assets
Cash And Cash Equivalents 83,507
Short-term Investments 222,709
Net Receivables 31,952
Inventory 21,210
Other Current Assets 21,718
Total Current Assets  (as reported)381,096
Total Current Assets  (calculated)381,096
+/-0
Long-term Assets
Property Plant Equipment 37,494
Long Term Investments 46,699
Long-term Assets Other 8,277
Long-term Assets  (as reported)92,470
Long-term Assets  (calculated)92,470
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities100,275
Long-term Liabilities22,375
Total Stockholder Equity350,916
Total Current Liabilities
Short-term Debt 3,504
Accounts payable 26,476
Other Current Liabilities 1,945
Total Current Liabilities  (as reported)100,275
Total Current Liabilities  (calculated)31,925
+/- 68,350
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt22,375
Long-term Liabilities  (as reported)22,375
Long-term Liabilities  (calculated)22,375
+/-0
Total Stockholder Equity
Common Stock805
Retained Earnings -1,428,305
Accumulated Other Comprehensive Income 577
Other Stockholders Equity 1,777,839
Total Stockholder Equity (as reported)350,916
Total Stockholder Equity (calculated)350,916
+/-0
Other
Capital Stock805
Cash and Short Term Investments 306,216
Common Stock Shares Outstanding 86,702
Current Deferred Revenue68,350
Liabilities and Stockholders Equity 473,566
Net Debt -57,628
Net Invested Capital 350,916
Net Working Capital 280,821
Property Plant and Equipment Gross 49,691
Short Long Term Debt Total 25,879



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-12-31
> Total Assets 
26,790
0
58,945
51,568
97,060
87,867
199,095
182,141
368,156
345,916
315,559
269,688
260,007
649,601
622,409
732,927
686,305
659,668
642,432
595,246
540,566
483,418
429,484
385,464
507,037
475,952
454,039
549,019
509,618
497,836
473,566
473,566497,836509,618549,019454,039475,952507,037385,464429,484483,418540,566595,246642,432659,668686,305732,927622,409649,601260,007269,688315,559345,916368,156182,141199,09587,86797,06051,56858,945026,790
   > Total Current Assets 
26,383
0
58,252
50,621
94,572
82,745
198,182
181,114
348,748
325,609
301,037
266,445
256,426
642,295
593,408
703,479
633,086
571,458
584,031
546,632
437,143
385,294
339,014
319,835
448,531
420,879
392,958
476,159
405,050
417,576
381,096
381,096417,576405,050476,159392,958420,879448,531319,835339,014385,294437,143546,632584,031571,458633,086703,479593,408642,295256,426266,445301,037325,609348,748181,114198,18282,74594,57250,62158,252026,383
       Cash And Cash Equivalents 
25,777
0
57,461
49,959
93,992
82,149
196,754
179,873
346,527
320,875
293,764
82,228
57,237
173,712
120,320
229,652
155,446
111,154
135,897
201,648
90,947
53,189
87,063
95,332
109,698
82,538
64,741
114,637
81,394
108,087
83,507
83,507108,08781,394114,63764,74182,538109,69895,33287,06353,18990,947201,648135,897111,154155,446229,652120,320173,71257,23782,228293,764320,875346,527179,873196,75482,14993,99249,95957,461025,777
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
180,114
168,179
460,883
459,256
461,848
454,890
434,171
416,033
300,527
304,405
289,081
198,571
161,221
274,149
282,039
259,745
283,996
247,346
230,988
222,709
222,709230,988247,346283,996259,745282,039274,149161,221198,571289,081304,405300,527416,033434,171454,890461,848459,256460,883168,179180,11400000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
25,000
0
0
100
7,384
11,814
13,896
21,821
18,608
18,049
20,595
23,151
25,851
23,278
22,429
22,439
23,200
27,549
31,952
31,95227,54923,20022,43922,42923,27825,85123,15120,59518,04918,60821,82113,89611,8147,3841000025,000000000000000
       Other Current Assets 
606
0
791
0
580
596
1,428
1,241
2,221
4,734
7,273
4,103
6,010
7,700
13,832
11,979
13,977
9,723
12,489
15,546
14,977
17,722
18,660
20,504
17,944
13,895
25,482
29,559
27,767
23,847
21,718
21,71823,84727,76729,55925,48213,89517,94420,50418,66017,72214,97715,54612,4899,72313,97711,97913,8327,7006,0104,1037,2734,7342,2211,2411,42859658007910606
   > Long-term Assets 
0
0
693
0
2,488
5,122
913
1,027
19,408
20,307
14,522
3,243
3,581
7,306
29,001
29,448
53,219
88,210
58,401
48,614
103,423
98,124
90,470
65,629
58,506
55,073
61,081
72,860
104,568
80,260
92,470
92,47080,260104,56872,86061,08155,07358,50665,62990,47098,124103,42348,61458,40188,21053,21929,44829,0017,3063,5813,24314,52220,30719,4081,0279135,1222,488069300
       Property Plant Equipment 
387
0
514
513
520
731
838
952
18,264
19,238
13,453
2,174
2,071
5,796
27,491
27,323
29,663
47,096
45,924
45,512
44,716
45,096
45,410
43,667
46,029
44,791
43,254
41,956
40,546
39,073
37,494
37,49439,07340,54641,95643,25444,79146,02943,66745,41045,09644,71645,51245,92447,09629,66327,32327,4915,7962,0712,17413,45319,23818,2649528387315205135140387
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
1,069
1,510
1,510
1,510
0
21,431
38,989
9,375
0
55,605
49,926
41,950
18,853
9,208
7,006
14,550
27,627
60,683
37,850
46,699
46,69937,85060,68327,62714,5507,0069,20818,85341,95049,92655,60509,37538,98921,43101,5101,5101,5101,06900000000000
       Long-term Assets Other 
0
0
179
0
1,968
4,391
75
75
75
1,069
1,069
1,069
1,510
1,510
1,510
2,125
2,125
2,125
3,102
3,102
3,102
3,102
3,110
3,109
3,269
3,276
3,277
3,277
3,339
3,337
8,277
8,2773,3373,3393,2773,2773,2763,2693,1093,1103,1023,1023,1023,1022,1252,1252,1251,5101,5101,5101,0691,0691,0697575754,3911,968017900
> Total Liabilities 
4,729
0
198,705
5,954
9,606
255,977
15,122
17,551
37,059
36,548
35,578
29,692
37,129
44,048
75,942
60,667
66,621
90,582
98,756
92,233
93,910
102,961
124,764
113,899
102,026
102,176
112,348
108,935
105,188
116,166
122,650
122,650116,166105,188108,935112,348102,176102,026113,899124,764102,96193,91092,23398,75690,58266,62160,66775,94244,04837,12929,69235,57836,54837,05917,55115,122255,9779,6065,954198,70504,729
   > Total Current Liabilities 
3,050
0
4,557
4,508
8,202
9,911
13,815
16,295
18,915
17,644
22,937
27,891
35,335
42,256
60,038
45,072
51,339
61,188
69,992
63,789
66,054
75,789
96,773
86,670
74,545
75,468
86,469
83,913
81,034
92,894
100,275
100,27592,89481,03483,91386,46975,46874,54586,67096,77375,78966,05463,78969,99261,18851,33945,07260,03842,25635,33527,89122,93717,64418,91516,29513,8159,9118,2024,5084,55703,050
       Short-term Debt 
187
0
187
1,622
187
187
187
187
187
187
187
621
500
602
1,747
1,501
1,424
2,010
2,457
2,540
2,604
2,662
2,870
2,931
3,102
3,170
3,235
3,301
3,368
3,436
3,504
3,5043,4363,3683,3013,2353,1703,1022,9312,8702,6622,6042,5402,4572,0101,4241,5011,7476025006211871871871871871871871,6221870187
       Short Long Term Debt 
187
0
187
1,622
1,575
187
187
187
187
187
187
187
187
187
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001871871871871871871871871871,5751,6221870187
       Accounts payable 
1,600
0
1,413
653
2,870
3,104
4,395
5,556
6,938
6,051
8,308
10,937
13,900
14,770
19,575
11,337
12,582
10,237
12,308
11,905
14,022
13,502
13,130
17,801
16,229
12,800
18,612
19,670
18,211
21,453
26,476
26,47621,45318,21119,67018,61212,80016,22917,80113,13013,50214,02211,90512,30810,23712,58211,33719,57514,77013,90010,9378,3086,0516,9385,5564,3953,1042,8706531,41301,600
       Other Current Liabilities 
1,263
0
2,957
0
5,145
6,789
9,233
10,552
11,790
11,406
14,248
16,333
20,935
26,884
38,716
32,234
37,333
48,941
55,227
49,344
49,428
59,625
1,071
65,938
55,214
59,498
64,622
60,942
3,399
4,547
1,945
1,9454,5473,39960,94264,62259,49855,21465,9381,07159,62549,42849,34455,22748,94137,33332,23438,71626,88420,93516,33314,24811,40611,79010,5529,2336,7895,14502,95701,263
   > Long-term Liabilities 
0
0
194,148
0
1,404
246,066
1,307
1,256
18,144
18,904
12,641
1,801
1,794
1,792
15,904
15,595
15,282
29,394
28,764
28,444
27,856
27,172
27,991
27,229
27,481
26,708
25,879
25,022
24,154
23,272
22,375
22,37523,27224,15425,02225,87926,70827,48127,22927,99127,17227,85628,44428,76429,39415,28215,59515,9041,7921,7941,80112,64118,90418,1441,2561,307246,0661,4040194,14800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
1,107
1,076
1,014
967
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000009671,0141,0761,1070000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
678
477
522
17,651
17,096
16,706
31,404
31,221
30,984
30,460
29,834
30,861
30,160
30,583
29,878
29,114
28,323
27,522
26,708
25,879
25,87926,70827,52228,32329,11429,87830,58330,16030,86129,83430,46030,98431,22131,40416,70617,09617,65152247767800000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
1,307
1,256
18,144
18,904
12,835
481
616
718
15,904
15,595
15,282
29,394
28,764
28,444
27,856
27,172
27,991
27,229
27,481
26,708
25,879
25,022
24,154
0
0
0024,15425,02225,87926,70827,48127,22927,99127,17227,85628,44428,76429,39415,28215,59515,90471861648112,83518,90418,1441,2561,307000000
       Deferred Long Term Liability 
0
0
104
359
1,893
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000001,89335910400
> Total Stockholder Equity
22,061
0
-139,760
-147,053
87,454
-168,110
183,973
164,590
331,097
309,368
279,981
239,996
222,878
605,553
546,467
672,260
619,684
569,086
543,676
503,013
446,656
380,457
304,720
271,565
405,011
373,776
341,691
440,084
404,430
381,670
350,916
350,916381,670404,430440,084341,691373,776405,011271,565304,720380,457446,656503,013543,676569,086619,684672,260546,467605,553222,878239,996279,981309,368331,097164,590183,973-168,11087,454-147,053-139,760022,061
   Common Stock
0
0
0
0
244
0
326
326
376
377
377
382
382
510
516
557
561
566
576
579
580
583
585
586
668
674
676
785
788
799
805
80579978878567667466858658558358057957656656155751651038238237737737632632602440000
   Retained Earnings Total Equity00-1,331,534-1,282,972-1,233,363-1,187,428-1,144,385-1,101,324-1,054,432-966,037-886,199-815,766-754,468-691,728-628,027-560,786-487,979-420,763-364,567-343,107-295,723-263,424-238,989-217,299-195,869000000
   Accumulated Other Comprehensive Income 
0
0
-766
0
-829
0
-915
-915
0
0
-1,217
21
175
61
111
763
-8
39
11
43
26
165
51
-563
-1,268
-2,042
-983
-181
-967
-896
577
577-896-967-181-983-2,042-1,268-5635116526431139-87631116117521-1,21700-915-9150-8290-76600
   Capital Surplus 
0
0
0
0
0
0
379,516
381,563
569,710
572,415
575,327
582,700
586,888
1,025,745
1,033,819
1,231,726
1,247,158
1,260,209
1,297,557
1,318,157
1,332,249
1,345,746
1,358,516
1,372,866
1,549,996
1,562,572
1,575,361
1,722,452
1,736,143
0
0
001,736,1431,722,4521,575,3611,562,5721,549,9961,372,8661,358,5161,345,7461,332,2491,318,1571,297,5571,260,2091,247,1581,231,7261,033,8191,025,745586,888582,700575,327572,415569,710381,563379,516000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
0
6,591
0
251,958
7,847
181,336
381,563
569,710
572,415
576,544
582,700
586,888
1,025,745
1,033,819
1,231,726
1,247,158
1,260,209
1,297,557
1,318,157
1,332,249
1,345,746
1,358,516
1,372,866
1,549,996
1,562,572
1,575,361
1,722,452
1,736,143
1,762,882
1,777,839
1,777,8391,762,8821,736,1431,722,4521,575,3611,562,5721,549,9961,372,8661,358,5161,345,7461,332,2491,318,1571,297,5571,260,2091,247,1581,231,7261,033,8191,025,745586,888582,700576,544572,415569,710381,563181,3367,847251,95806,59100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue163,356
Cost of Revenue-3,732
Gross Profit159,624159,624
 
Operating Income (+$)
Gross Profit159,624
Operating Expense-370,582
Operating Income-210,958-210,958
 
Operating Expense (+$)
Research Development234,123
Selling General Administrative129,506
Selling And Marketing Expenses0
Operating Expense370,582363,629
 
Net Interest Income (+$)
Interest Income13,916
Interest Expense-0
Other Finance Cost-0
Net Interest Income13,916
 
Pretax Income (+$)
Operating Income-210,958
Net Interest Income13,916
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-194,511-227,405
EBIT - interestExpense = -210,958
-194,511
-194,942
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-210,958-194,511
Earnings Before Interest and Taxes (EBITDA)-210,958
 
After tax Income (+$)
Income Before Tax-194,511
Tax Provision-431
Net Income From Continuing Ops-193,687-194,942
Net Income-194,942
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses374,314
Total Other Income/Expenses Net16,447-13,916
 

Technical Analysis of Deciphera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Deciphera. The general trend of Deciphera is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Deciphera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Deciphera Pharmaceuticals LLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 14.65 < 14.74 < 15.81.

The bearish price targets are: 13.86 > 13.25 > 13.17.

Tweet this
Deciphera Pharmaceuticals LLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Deciphera Pharmaceuticals LLC. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Deciphera Pharmaceuticals LLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Deciphera Pharmaceuticals LLC. The current macd is -0.26573516.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Deciphera price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Deciphera. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Deciphera price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Deciphera Pharmaceuticals LLC Daily Moving Average Convergence/Divergence (MACD) ChartDeciphera Pharmaceuticals LLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Deciphera Pharmaceuticals LLC. The current adx is 15.36.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Deciphera shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Deciphera Pharmaceuticals LLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Deciphera Pharmaceuticals LLC. The current sar is 15.76.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Deciphera Pharmaceuticals LLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Deciphera Pharmaceuticals LLC. The current rsi is 42.63. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Deciphera Pharmaceuticals LLC Daily Relative Strength Index (RSI) ChartDeciphera Pharmaceuticals LLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Deciphera Pharmaceuticals LLC. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Deciphera price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Deciphera Pharmaceuticals LLC Daily Stochastic Oscillator ChartDeciphera Pharmaceuticals LLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Deciphera Pharmaceuticals LLC. The current cci is -166.76679082.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Deciphera Pharmaceuticals LLC Daily Commodity Channel Index (CCI) ChartDeciphera Pharmaceuticals LLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Deciphera Pharmaceuticals LLC. The current cmo is -17.82324536.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Deciphera Pharmaceuticals LLC Daily Chande Momentum Oscillator (CMO) ChartDeciphera Pharmaceuticals LLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Deciphera Pharmaceuticals LLC. The current willr is -64.77272727.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Deciphera is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Deciphera Pharmaceuticals LLC Daily Williams %R ChartDeciphera Pharmaceuticals LLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Deciphera Pharmaceuticals LLC.

Deciphera Pharmaceuticals LLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Deciphera Pharmaceuticals LLC. The current atr is 0.63207241.

Deciphera Pharmaceuticals LLC Daily Average True Range (ATR) ChartDeciphera Pharmaceuticals LLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Deciphera Pharmaceuticals LLC. The current obv is 7,205,154.

Deciphera Pharmaceuticals LLC Daily On-Balance Volume (OBV) ChartDeciphera Pharmaceuticals LLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Deciphera Pharmaceuticals LLC. The current mfi is 25.76.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Deciphera Pharmaceuticals LLC Daily Money Flow Index (MFI) ChartDeciphera Pharmaceuticals LLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Deciphera Pharmaceuticals LLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Deciphera Pharmaceuticals LLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Deciphera Pharmaceuticals LLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.628
Ma 20Greater thanMa 5015.159
Ma 50Greater thanMa 10015.648
Ma 100Greater thanMa 20015.202
OpenGreater thanClose14.170
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Deciphera with someone you think should read this too:
  • Are you bullish or bearish on Deciphera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Deciphera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Deciphera Pharmaceuticals LLC

I send you an email if I find something interesting about Deciphera Pharmaceuticals LLC.


Comments

How you think about this?

Leave a comment

Stay informed about Deciphera Pharmaceuticals LLC.

Receive notifications about Deciphera Pharmaceuticals LLC in your mailbox!